Neither Clonidine nor Guanfacine Shows Clear Superiority for PTSD Treatment
The available evidence does not support the use of either clonidine or guanfacine as first-line treatments for PTSD symptoms, and there is insufficient data to determine which agent is superior. Both medications have limited, low-quality evidence for PTSD treatment, with clonidine having slightly more clinical experience but guanfacine showing mixed results in controlled trials.
Evidence Quality and Recommendations
Clonidine for PTSD
Clonidine may be considered for PTSD-associated nightmares (Level C recommendation) 1. However, this recommendation is based on:
- Only 2 Level 4 case series showing efficacy in 11/13 Cambodian refugees (no statistical analysis)
- Doses of 0.2-0.6 mg in divided doses
- No randomized placebo-controlled trials exist despite over 20 years of clinical use 1
- The paucity of rigorous data relegates this to a lower-level recommendation despite pharmacologic similarity to prazosin (which has Level A evidence)
A recent retrospective study of 79 veterans found that 72% experienced improvement with low-dose clonidine, with 49% scoring "much improved" or "very much improved" on CGI scales 2. However, this lacks the rigor of controlled trials.
Guanfacine for PTSD
The evidence for guanfacine is even more problematic:
A randomized controlled trial in veterans showed guanfacine had NO effect on PTSD symptoms 3. This 8-week, double-blind study of 63 veterans (29 guanfacine, 34 placebo) found:
- No improvement in PTSD symptoms
- No improvement in subjective sleep quality
- No improvement in general mood disturbances
- Associated with multiple side effects
This directly contradicts the use of guanfacine in adult PTSD patients.
The only positive evidence comes from:
- An open-label pediatric study (n=19) showing improvement in traumatic stress symptoms 4
- A single case report in a 15-year-old with complex PTSD 5
Direct Comparison Data
In pediatric populations, clonidine showed faster onset than guanfacine (1.59 vs 3.18 days to nightmare reduction, p=0.005), though both were effective 6. However, this pediatric data cannot be extrapolated to adults given the negative adult RCT for guanfacine.
A meta-analysis comparing clonidine to prazosin/terazosin showed no difference in nightmare reduction (OR: 1.16; 95% CI: 0.66-2.05), suggesting potential non-inferiority between these agents 7.
Mechanism and Formulation Considerations
Both agents are α2-adrenergic agonists that reduce sympathetic outflow 1, 8, 9. Key differences:
- Guanfacine is 10-25 times less potent than clonidine 8
- Guanfacine has higher specificity for α2A receptors, potentially causing less sedation 8
- No evidence exists comparing IR vs ER formulations for PTSD treatment—all PTSD studies used immediate-release formulations
The ADHD literature (where both are FDA-approved) shows similar adverse effect profiles: somnolence, fatigue, irritability, insomnia, and nightmares 8. Notably, nightmares are listed as an adverse effect of both medications in ADHD treatment, which is paradoxical given their proposed use for PTSD nightmares.
Clinical Algorithm
If considering an α2-agonist for PTSD (recognizing neither is first-line):
First-line treatment remains SSRIs (sertraline, paroxetine—FDA-approved for PTSD) 9
If hyperarousal/nightmares persist despite SSRI:
- Consider prazosin (α1-antagonist) first—Level A evidence 1
If prazosin fails or is contraindicated:
- Clonidine 0.1 mg at bedtime, titrate by 0.1 mg every few days to 0.2-0.4 mg total daily dose (divided)
- Monitor for orthostatic hypotension, sedation, bradycardia
- Evidence limited to case series but has 20+ years clinical experience 1
Avoid guanfacine in adult PTSD given the negative RCT 3
Critical Caveats
- Neither medication is FDA-approved for PTSD
- The 2024 VA/DoD PTSD guidelines do not specifically recommend α2-agonists 10
- Both medications can paradoxically cause nightmares as an adverse effect 8, 11
- Abrupt discontinuation can cause rebound hypertension—taper gradually 11
- Cardiovascular monitoring required: baseline and follow-up BP, heart rate 8, 11
- Guanfacine's negative adult RCT is the highest quality evidence available and should guide practice
The evidence strongly suggests that if an α2-agonist is to be used for PTSD, clonidine has marginally more support than guanfacine, though both remain far inferior to prazosin or SSRIs.